INDICATIONS AND USAGE FOR SANDOSTATIN LAR DEPOT

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) injection has been shown to be effective and tolerated for:

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

*Includes Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for all approved indications.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.
Real people.
Real stories.
Real life.

We’ve created this guide to help you live with the severe diarrhea and flushing associated with carcinoid syndrome. As you read through, you’ll be introduced to people just like you who are managing these symptoms with Sandostatin® LAR Depot (octreotide acetate) for injectable suspension.

SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
If you are newly diagnosed, or just starting treatment with Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, you might be feeling a little overwhelmed. There’s so much to learn! No need to worry, we can help you get off to a great start. This information is for educational purposes, and is not intended to substitute the advice and guidance of your health care provider.

The information in this brochure is organized by topic, so you can take it step by step—or jump ahead if you need to know something right away. Here is how this content is organized:

1. Carcinoid syndrome: what it is, and symptoms you may have

2. Testing and treatment: learn about a commonly used urine test, and how Sandostatin LAR Depot can help control your severe diarrhea and flushing

3. Starting Sandostatin: information to guide you through your first 2 weeks of daily dosing and the transition to monthly dosing with Sandostatin LAR Depot

4. Managing your symptoms: tips to help manage your diagnosis, and dietary advice to help avoid triggering symptoms

5. Frequently asked questions: answers to questions you may have about your treatment

6. Support: 5 key programs that make it easier for you to access your treatment and get the most benefit from it

7. Resources: a quick guide to advocacy and support groups

Let’s get started!

SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
Carcinoid syndrome refers to the group of symptoms that result from active carcinoid tumors. When carcinoid tumors start to spread, or metastasize, they can cause sudden and severe symptoms. These symptoms are the result of an increased release of hormones by the carcinoid tumors.

Throughout this guide, you’ll see words like carcinoid tumor and carcinoid syndrome—things you’ll hear your health care provider talk about, too. Our goal is to make the information as easy to understand as possible.

What causes the symptoms of carcinoid syndrome?

Neuroendocrine tumors (NET) form in the cells of the neuroendocrine system. NET can form in the digestive system or lung and are also known as carcinoid tumors.

Most carcinoid tumors occur in the gastrointestinal tract.

There are 2 types of carcinoid tumors. Your doctor may refer to them as “functional” or “nonfunctional”. Functional carcinoid tumors release large amounts of hormones, such as serotonin, into the body.

It’s these excess hormones that can cause a variety of symptoms, including the severe diarrhea and flushing associated with carcinoid syndrome.

IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
Now we’re going to talk about what you may be experiencing.

The symptoms associated with functional carcinoid tumors can be subtle and common to other disorders. They may also come and go, and be more severe at certain times than others. That’s why it may have taken some time for you to get a diagnosis of carcinoid syndrome. If this happened to you, you’re not alone.

What are the most common symptoms of carcinoid syndrome?

**Diarrhea (loose, watery stools)**
- Can be mild to severe
- May occur during the night
- Can occur several times a day

**Flushing (red or purplish skin)**
- Appears suddenly
- Temporary (lasting minutes) or prolonged (lasting hours)
- Primarily on the face or neck
- May be accompanied by warmth and/or a rapid heartbeat

Different people experience symptoms differently. Some people have mild diarrhea and constant flushing, but for others it may be the other way around. You may experience both at the same time or you may have one without the other.

The most important thing is to talk to your health care provider if you have any new symptoms or an increase in the symptoms you already have—no matter how mild or severe you think they are.

**SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN® LAR DEPOT (OCTREOTIDE ACETATE) FOR INJECTABLE SUSPENSION (CONTINUED)**

**Common Side Effects:** Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

**Other Information:** Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
You may want to ask your health care provider:
How long will it take to get my test results?

**TESTING & TREATMENT**

How can a test prove I have the severe diarrhea and flushing associated with carcinoid syndrome?

Once your health care provider has determined that you may have carcinoid syndrome, he or she will perform tests that will help confirm your diagnosis.

One of the hormones overproduced by functional carcinoid tumors is serotonin, which is broken down into a substance called 5-hydroxyindoleacetic acid (5-HIAA, for short). To find out if you have carcinoid syndrome, your health care provider will take a sample of your blood and/or urine to measure your levels of 5-HIAA.

Before you take this test, there are some foods you shouldn’t eat, because they can affect the results. Your health care provider will tell you about them, but here’s a reminder:

- Avocados
- Bananas
- Pineapples
- Pecans
- Tomatoes
- Walnuts/Hickory nuts

There are also some medicines you shouldn’t take before your 5-HIAA test. Again, your health care provider will tell you, but here’s a reminder:

- Acetaminophen (such as Tylenol®)
- Salicylates (such as aspirin)
- Guaifenesin (found in some cough medicines)
- L-dopa (used to treat Parkinson disease)

Tylenol® is a registered trademark of McNeil Consumer Healthcare.

Joe

“My daughter’s graduation from nursing school was no small affair. And I didn’t miss a moment. It was my proudest day.”

---

**SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT**

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
When you get a diagnosis of severe diarrhea and flushing associated with carcinoid syndrome, your first thought may be, “Is there a way to treat this?” For decades, the answer has been “Yes!” Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin® LAR Depot (octreotide acetate) for injectable suspension have been helping patients reduce these symptoms of carcinoid syndrome. With more than a million patient-years of treatment experience worldwide*, Sandostatin Immediate-Release Injection and Sandostatin LAR Depot provide control you can trust.

Symptom control you can count on.

Here are results from a clinical study of 93 patients with carcinoid syndrome who were treated with Sandostatin LAR Depot or Sandostatin Immediate-Release Injection.

**Sandostatin LAR Depot REDUCES DAILY STOOLS**

<table>
<thead>
<tr>
<th>Sandostatin LAR Depot</th>
<th>REDUCES DAILY STOOLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3 STOOLS PER DAY</td>
<td>2.5 STOOLS PER DAY</td>
</tr>
</tbody>
</table>

**Sandostatin LAR Depot REDUCES FLUSHING**

<table>
<thead>
<tr>
<th>Sandostatin LAR Depot</th>
<th>REDUCES FLUSHING</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5 EPISODES PER DAY</td>
<td>0.7 EPISODES PER DAY</td>
</tr>
</tbody>
</table>

*A 6-month clinical trial of malignant carcinoid syndrome was performed in patients who had previously been shown to be responsive to Sandostatin Immediate-Release Injection. Patients received 10-mg, 20-mg, or 30-mg doses of Sandostatin LAR Depot every 28 days or continued their Sandostatin Immediate-Release Injection regimen. Patients receiving Sandostatin LAR Depot who experienced symptom flare-ups were permitted to use supplemental Sandostatin Immediate-Release Injection until symptoms were again controlled to screening frequency.

**SOME IMPORTANT THINGS YOU SHOULD KNOW ABOUT SANDOSTATIN LAR DEPOT**

All prescription medications have possible side effects. Here are some with which you should be familiar before starting Sandostatin LAR Depot.

**Sandostatin LAR Depot may affect:**

- Gallbladder function
- Thyroid function
- Nutritional absorption
- Sugar metabolism
- Heart function

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

**The most common side effects of Sandostatin LAR Depot include:**

- Back pain
- Headache
- Nausea
- Fatigue
- Abdominal pain
- Dizziness
- Thyroid function
- Nutritional absorption

**Other Information:** Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

These are not all the possible side effects of Sandostatin LAR Depot. For more information, ask your doctor or pharmacist.

**Report side effects you may experience with Sandostatin LAR Depot to the FDA.**

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please [click here](http://www.sandostatin.com) for full Prescribing Information for Sandostatin Immediate-Release Injection and [click here](http://www.sandostatin.com) for Sandostatin LAR Depot.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit [us.sandostatin.com](http://us.sandostatin.com).
You're about to start therapy with Sandostatin® LAR Depot (octreotide acetate) for injectable suspension. This is an important step toward controlling your symptoms rather than having them control you. Below is a quick guide to getting started.

**Begin with Sandostatin**

If your health care provider has prescribed Sandostatin® (octreotide acetate) Immediate-Release Injection to you for the first time, you will start by getting daily injections.

**Two reasons why it is important to begin your therapy with daily injections:**

- Your health care provider can see how well Sandostatin Immediate-Release Injection is working from the start
- Your health care provider can see if you’re experiencing any common side effects, such as back pain, fatigue, headache, abdominal pain, nausea, and dizziness

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

**SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT**

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please [click here](http://www.1-888-now-nova.com) for full Prescribing Information for Sandostatin Immediate-Release Injection and [click here](http://www.sandostatin.com) for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
Switching to Sandostatin LAR Depot.

Your health care provider will monitor your progress on Sandostatin® (octreotide acetate) Immediate-Release Injection for at least 2 weeks and may then prescribe Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, which will be given as an injection by your health care provider once every 4 weeks.

During the first month:

Your health care provider will ask you to continue taking daily injections for at least 2 more weeks—just to make sure you have appropriate symptom control while the Sandostatin LAR Depot starts working. You may be given supplemental Sandostatin Immediate-Release Injection (at the dose you were previously receiving) if you experience symptom flare-ups while on Sandostatin LAR Depot.

After 2 months:

Your health care provider will check on your progress to see if the dose should be adjusted. Remember to talk about any symptoms you’re having. Try to be as accurate as possible so you can get the right dose. You should also be visiting your health care provider every 4 weeks to check in.

You may want to ask your health care provider: What are the side effects of treatment?

SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
When you have excessive diarrhea, you can lose a lot of water. That means you could become dehydrated and lose electrolytes. It can also affect your digestion and cause changes in your body weight and nutrition absorption, which can leave you feeling weak and tired.

Here are some additional tips for what you can do to help you manage the severe diarrhea and flushing associated with carcinoid syndrome.

<table>
<thead>
<tr>
<th>Stay hydrated:</th>
<th>Drink plenty of water each day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep your energy up:</td>
<td>Eat high-protein foods like lean meats, fish, and eggs</td>
</tr>
<tr>
<td>Make digestion easier:</td>
<td>Cook or finely chop hard-to-digest fruits and vegetables</td>
</tr>
<tr>
<td>Avoid foods rich in amines:</td>
<td>Aged cheeses, pickled foods, cured meats</td>
</tr>
<tr>
<td>Reduce stress:</td>
<td>Try to keep a positive attitude every day</td>
</tr>
<tr>
<td>Eat simply:</td>
<td>Avoid large, spicy meals</td>
</tr>
<tr>
<td>Keep a journal:</td>
<td>Identifying foods and situations that trigger symptoms can help you avoid them</td>
</tr>
</tbody>
</table>

Most patients experience some common side effects such as back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please [click here](http://sandostatin.com) for full Prescribing Information for Sandostatin Immediate-Release Injection and [click here](http://sandostatin.com) for Sandostatin LAR Depot.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit [us.sandostatin.com](http://us.sandostatin.com).
Enjoy great food by watching what you can eat.

When you’re managing the severe diarrhea and flushing associated with carcinoid syndrome, watching what you eat may help you avoid some symptoms or symptom flare-ups. But that doesn’t mean that mealtimes must be boring.

Here are some tips for happy, healthy eating:

Eat this:

- Canned or cooked fruits and veggies
- Crackers and pretzels
- Clear broth soup
- Jelly

Not that:

- Raw fruits and veggies
- Butter cookies and donuts
- Creamy soup
- Butter and cream cheese

Try some new recipes.
Break out of your routine with some great new recipes developed especially for people with carcinoid syndrome. You’ll find them online on our Facebook page: www.facebook.com/SandostatinLARDepot

Learn from the pros.
Watch our Chef at Home videos to see how the pros make mealtimes delicious and enjoyable for you and the whole family. You can access the videos by visiting our Facebook page: www.facebook.com/SandostatinLARDepot

You may want to ask your health care provider: How much protein should I be eating each day?

Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
FAQs

You have questions. We have answers.

And if you don’t see what you need, visit us.sandostatin.com for more information or talk to your health care provider.

Q: How does Sandostatin® LAR Depot (octreotide acetate) for injectable suspension work?
A: Sandostatin LAR Depot is similar to somatostatin, a hormone that occurs naturally in the body. Both work in the same way to reduce excess hormones and other metabolic activities involved in carcinoid syndrome and VIPomas*. Sandostatin LAR Depot remains in the body much longer than somatostatin.

Q: What dose of Sandostatin LAR Depot is right for me?
A: Sandostatin LAR Depot comes in 3 doses. Talk to your doctor to find out which dose is right for you.

Q: Can I administer Sandostatin LAR Depot to myself?
A: No, Sandostatin LAR Depot should be administered only by a trained health care provider.

Q: What should I do if I miss an appointment?
A: If you miss your appointment for your injection, you should call your health care provider’s office immediately to reschedule your visit. If keeping office appointments is difficult for you, talk with your health care provider to see if you qualify for the Mobile Administration Program (MAP). If your health care provider determines you are eligible for MAP, he or she will fill out and submit an enrollment form for you. Then a representative will contact you to schedule your first appointment with a nurse who will administer your injection at a location and time convenient for you.

Q: Can I stop taking Sandostatin LAR Depot if I feel better?
A: You should consult with your health care provider. You may feel better because of the action of Sandostatin LAR Depot, but the underlying problem still exists.

*VIPomas, vasoactive intestinal peptide tumors.
Q: How much does Sandostatin® LAR Depot (octreotide acetate) for injectable suspension cost?
A: How much the drug will cost depends on where it is dispensed and what your individual insurance plan may cover. This amount can vary.

Q: How can I get help paying for my Sandostatin LAR Depot?
A: Novartis is committed to providing access to the treatments you need. With the Novartis Oncology Universal Co-pay Card, eligible, commercially insured patients may pay no more than $25 per Sandostatin LAR Depot prescription. To find out if you are eligible, visit CoPay.NovartisOncology.com, or call 1-877-577-7756.

Limitations apply. See program terms and conditions at CoPay.NovartisOncology.com. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.

Q: What are the possible side effects of Sandostatin LAR Depot, which is taken to treat the severe diarrhea and flushing associated with carcinoid syndrome?
A: Most patients experience side effects at some time. Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.
SUPPORT
We’re here for you providing the resources, support, and information you need.

No one should have to go through anything as tough as carcinoid syndrome alone. That’s why Novartis has been providing support to patients with carcinoid syndrome for decades.* Here are 5 key support programs designed to help patients do all that they can to get the most out of their treatment and to control symptoms of severe diarrhea and flushing associated with metastatic carcinoid tumors:

1 The RealSupport™ program—your key to a library of materials

An information and support program specifically designed to provide the nutrition materials and tools needed to manage the severe diarrhea and flushing associated with carcinoid syndrome. Learn from the experts, see and hear real patient stories, and enjoy our library of recipes and other tools for managing carcinoid syndrome.

2 The Sandostatin LAR Depot Facebook Page—a community of support and information

Get connected—Like and Follow us on www.facebook.com/SandostatinLARDepot

Join us on Facebook to connect with people living with carcinoid syndrome and get access to recipes, cooking demonstrations, and stories from patients like you.

*Includes Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for all approved indications.

SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
If you’re an eligible patient, once your health care professional finds the right dose of Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for you, you may be able to get your injections on the go. Talk to your health care professional to find out if the Mobile Administration Program (MAP) is right for you.†

- Of course, this shouldn’t replace regularly scheduled appointments with your health care professional. The first dose of Sandostatin LAR Depot must be administered by your treating physician. But with MAP, subsequent doses can be administered in a place that’s convenient for you, even outside of normal office hours.
- All MAP nurses are registered nurses affiliated with United BioSource Corporation—specially trained in the mixing and administration of Sandostatin LAR Depot.
- Talk to your health care professional to find out if the MAP is right for you.

*Some restrictions may apply.
† Patients with government-provided insurance (such as Medicare Parts B and D or Medicaid) are not eligible at this time. Patients who reside in Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for this program. Visit us.sandostatin.com for complete terms and conditions.

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.

Patient Assistance Now Oncology—helping you get the medicines you need

To learn more, call 1-800-282-7630 or visit Patient.NovartisOncology.com.

You may be eligible for immediate co-pay savings on your next prescription.

- Eligible patients with private insurance may pay $25 per month*
- Novartis will pay the remaining co-pay, up to $15,000 per calendar year.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit CoPay.NovartisOncology.com or call 1-877-577-7756.

To find out if you are eligible for the Universal Co-pay Program, call 1-877-577-7756 or visit CoPay.NovartisOncology.com.

SELECTED IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot and for Sandostatin Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot. To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.
RESOURCES

There’s also a host of support groups and organizations that have your back, too.

**NET advocacy groups***

<table>
<thead>
<tr>
<th>Advocacy Group</th>
<th>Website</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoid Cancer Foundation (CCF)</td>
<td><a href="http://www.carcinoid.org">www.carcinoid.org</a></td>
<td>1-888-722-3132 (toll free)</td>
</tr>
<tr>
<td>Neuroendocrine Tumor (NET) Research Foundation</td>
<td><a href="http://www.netrf.org">www.netrf.org</a></td>
<td>1-617-946-1780</td>
</tr>
<tr>
<td>Los Angeles Carcinoid Neuroendocrine Tumor Society</td>
<td><a href="http://www.lacnets.org">www.lacnets.org</a></td>
<td></td>
</tr>
<tr>
<td>Healing NET Foundation</td>
<td><a href="http://www.thehealingnet.org">www.thehealingnet.org</a></td>
<td>1-615-369-6463</td>
</tr>
<tr>
<td>Neuroendocrine Cancer Awareness Network (NCAN)</td>
<td><a href="http://www.netcancerawareness.org">www.netcancerawareness.org</a></td>
<td>1-866-850-9555 (toll free)</td>
</tr>
<tr>
<td>NorCal CarciNET Community</td>
<td><a href="http://norcalcarcinet.org">norcalcarcinet.org</a></td>
<td></td>
</tr>
</tbody>
</table>

*These websites are maintained by third parties. Novartis Pharmaceuticals Corporation does not guarantee the accuracy, completeness, or any other aspect of the information on these sites.

**Important Safety Information**

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension

**INDICATIONS AND USAGE**

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

**IMPORTANT SAFETY INFORMATION**

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

**Common Side Effects:** Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

**Other Information:** Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Please click here for full Prescribing Information for Sandostatin LAR Depot.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit [us.sandostatin.com](http://us.sandostatin.com).

**Get connected—Like and Follow us on [www.facebook.com/SandostatinLARDepot](http://www.facebook.com/SandostatinLARDepot)**
**Common Side Effects:** Most patients experience side effects at some time. Some common side effects you may experience include gallstones, heart function changes, diarrhea, loose stools, nausea, abdominal discomfort, flatulence, blood sugar changes, underactive thyroid gland including enlarged thyroid gland, pain on injection, headache, dizziness and inflammation of the pancreas.

**Other Information:** Women of child bearing potential should use adequate contraception during treatment. Talk to your doctor if you are a nursing mother. Diabetic patients should monitor their blood sugar levels frequently. Patients should make sure they are carefully instructed in the correct sterile injection technique before using Sandostatin Injection.

Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

**Important Safety Information**

**INDICATIONS AND USAGE**
Sandostatin Injection is a prescription medicine indicated for
- Treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Treatment of the profuse watery diarrhea associated with VIP-secreting tumors

The effect of Sandostatin Injection on tumor size, rate of growth and development of metastases has not been determined.

**IMPORTANT SAFETY INFORMATION**

**Warnings and Precautions:** Treatment with Sandostatin® (octreotide acetate) Injection may affect gallbladder function, with postmarketing reports of gallstones resulting in complications requiring surgical removal of the gallbladder; sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications (eg, inflammation of the gallbladder, bile duct, or pancreas).

**Before Taking Sandostatin Injection:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, calcium channel blockers, agents to control fluid and electrolyte balance, and bromocriptine.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection.
Is your mind spinning with questions and information? Jot it all down here so you don’t forget!

Notes

Please see Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 16 and 17, respectively.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit us.sandostatin.com.